Provided by Tiger Trade Technology Pte. Ltd.

Silexion Therapeutics Corp

0.4317
+0.081923.43%
Volume:108.68M
Turnover:48.72M
Market Cap:2.48M
PE:-0.01
High:0.4859
Open:0.4123
Low:0.3912
Close:0.3495
52wk High:77.70
52wk Low:0.3350
Shares:5.76M
Float Shares:5.67M
Volume Ratio:1,763.00
T/O Rate:1916.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-56.4473
EPS(LYR):-89.5962
ROE:-897.46%
ROA:-123.27%
PB:56.47
PE(LYR):0.00

Loading ...

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

GlobeNewswire
·
Sep 09

After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)

TIPRANKS
·
Aug 25

Silexion Therapeutics Announces Extraordinary Shareholder Meeting

Reuters
·
Aug 25

Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall

Reuters
·
Aug 22

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)

TIPRANKS
·
Aug 20

Silexion Therapeutics Announces Extraordinary General Meeting

Reuters
·
Aug 15

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 14

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Top Premarket Decliners

MT Newswires Live
·
Aug 12

Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants

Reuters
·
Aug 12

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

THOMSON REUTERS
·
Aug 12

Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)

TIPRANKS
·
Aug 11

Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers

Reuters
·
Aug 09

Silexion Therapeutics files to sell ordinary shares, warrants, no amount given

TIPRANKS
·
Aug 08

Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers

Reuters
·
Aug 04

Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells

THOMSON REUTERS
·
Aug 04

Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons

Reuters
·
Aug 01

Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)

TIPRANKS
·
Jul 29

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

THOMSON REUTERS
·
Jul 29

Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months

THOMSON REUTERS
·
Jul 29